Ironwood Pharmaceuticals Inc (IRWD)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 72.15% | 71.46% | 73.44% | 78.16% | 78.35% | 78.87% | 78.63% | 79.39% | 78.98% | 78.95% | 76.52% | 73.71% | 69.70% | 70.48% | 68.77% | 64.26% | 55.41% | 55.93% | -0.57% | -14.43% |
| Operating profit margin | -220.10% | -218.19% | -209.72% | 61.40% | 61.85% | 57.53% | 58.02% | 60.53% | 59.26% | 58.00% | 53.60% | 46.62% | 39.56% | 38.05% | 43.99% | 39.79% | 32.38% | 26.74% | -32.46% | -45.81% |
| Pretax margin | -213.89% | -209.32% | -198.99% | 63.66% | 62.38% | 54.60% | 53.31% | 53.63% | 51.20% | 50.81% | 45.21% | 38.82% | 30.13% | 30.25% | 26.45% | 22.27% | 5.80% | -11.15% | -68.59% | -92.19% |
| Net profit margin | -233.32% | -227.17% | -217.08% | 44.24% | 43.26% | 40.41% | 42.69% | 130.44% | 134.83% | 135.46% | 131.44% | 38.00% | 29.39% | 29.88% | 26.45% | 22.27% | 5.80% | -11.15% | -68.59% | -92.19% |
Ironwood Pharmaceuticals Inc's profitability ratios exhibit fluctuating trends over the quarters provided.
The gross profit margin remained consistently at 100% across all quarters, indicating that the company is able to generate revenue efficiently and effectively manage its cost of goods sold.
The operating profit margin showed significant variability, ranging from 38.02% to 60.55%. The declining trend from Q4 2022 to Q1 2023 suggests potential challenges in controlling operating expenses relative to sales revenue. However, there was a slight improvement in profitability in Q3 2023.
The pretax margin saw substantial negative margins in the most recent quarters, reflecting higher expenses that impacted the company's earnings before taxes. The significant negative margins in Q4 2023 and Q3 2023 indicate that the company may be facing significant non-operating expenses or one-time charges during those periods.
The net profit margin also displayed a mix of negative and positive performance, with the most recent quarters featuring notably large negative margins. This indicates that Ironwood Pharmaceuticals Inc may have experienced challenges in generating profits after accounting for all expenses, including taxes.
Overall, the company's profitability ratios suggest that Ironwood Pharmaceuticals Inc may be facing some operational and financial challenges impacting its ability to generate sustainable profits in the recent quarters.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -200.70% | -174.53% | -146.91% | 21.86% | 22.75% | 22.93% | 24.11% | 22.59% | 20.61% | 21.04% | 20.60% | 29.22% | 25.56% | 28.67% | 36.39% | 37.20% | 29.83% | 30.03% | -35.50% | -40.80% |
| Return on assets (ROA) | -212.76% | -181.71% | -152.07% | 15.75% | 15.91% | 16.11% | 17.74% | 48.67% | 46.89% | 49.13% | 50.52% | 23.82% | 18.99% | 22.51% | 21.88% | 20.82% | 5.34% | -12.52% | -75.02% | -82.11% |
| Return on total capital | -590.16% | -431.52% | -330.77% | 24.34% | 24.80% | 24.36% | 25.48% | 26.58% | 24.57% | 25.15% | 24.42% | 32.17% | 28.61% | 32.19% | 42.20% | 43.96% | 38.17% | 40.22% | -84.03% | -120.68% |
| Return on equity (ROE) | — | — | — | 25.74% | 26.83% | 28.35% | 32.48% | 101.84% | 87.22% | 91.44% | 99.43% | 129.55% | 169.50% | 1,877.20% | — | — | — | — | — | — |
Ironwood Pharmaceuticals Inc's profitability ratios show fluctuations over the past eight quarters. The Operating return on assets (Operating ROA) ranged from 21.86% to 36.92%, indicating the company's ability to generate profits from its assets before interest and taxes. However, the Return on assets (ROA) was negative in the last four quarters, suggesting that the company experienced losses during those periods.
On the other hand, the Return on total capital varied from 22.89% to 48.46%, demonstrating the efficiency of the company in generating profits from its total invested capital. The Return on equity (ROE) also displayed variability, showing an ability to generate returns for shareholders ranging from 25.74% to a high of 101.84%.
Overall, Ironwood Pharmaceuticals Inc's profitability ratios reflect a mix of strong performance and challenges, highlighting the need for further investigation into the factors influencing these fluctuations.